The clinical trial, sponsored by Qianfoshan Hospital, aims to evaluate the efficacy of CAZ-AVI in combination with ATM against MBL-producing Enterobacterales, a significant concern in antibiotic resistance. The study's focus on CRISPR/Cas9 technology to eliminate resistance genes positions it at the forefront of innovative treatment strategies in the antibiotic space. Given the rising prevalence of carbapenem-resistant infections, successful outcomes could lead to substantial market opportunities, particularly in regions with high rates of antibiotic resistance. The trial is currently recruiting, with an estimated completion date in January 2025, indicating a potential for timely entry into a growing market segment. However, the overall status remains unknown, necessitating close monitoring of recruitment and interim results to assess commercial viability.